Chromadex Corp.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ICLRICON plc -0.09%190.842.7%$94.76m
ARGXargenx SE -3.79%343.200.0%$74.92m
VRXValeant Pharmaceuticals International, Inc. -1.26%7.0614.1%$41.54m
BRBRBellRing Brands, Inc. -0.18%21.710.0%$20.03m
RVMDRevolution Medicines, Inc. 0.11%18.430.0%$16.82m
BGXXBright Green Corp. 1.63%1.250.0%$6.91m
USNAUSANA Health Sciences, Inc. -0.33%58.354.2%$3.68m
ANIKAnika Therapeutics, Inc. 0.04%23.479.7%$1.99m
ENVBEnveric Biosciences, Inc. -3.40%4.540.0%$0.62m
IBIOiBio, Inc. -6.76%0.350.2%$0.60m
NATRNature's Sunshine Products, Inc. -1.60%8.610.4%$0.42m
FLGCFlora Growth Corp. -3.51%0.880.0%$0.34m
BPTSBiophytis SA 0.00%0.660.0%$0.31m
GHSIGuardion Health Sciences, Inc. 7.99%0.150.0%$0.24m
CDXCChromadex Corp. -6.20%1.212.7%$0.19m

Company Profile

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.